Blue Fin Capital’s iShares Biotechnology ETF IBB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q3 | $2.12M | Buy |
10,053
+32
| +0.3% | +$6.42K | 0.29% | 58 |
|
|
2026
Q2 | $1.91M | Buy |
10,021
+32
| +0.3% | +$5.5K | 0.28% | 59 |
|
|
2026
Q1 | $1.69M | Buy |
9,989
+95
| +1% | +$16.2K | 0.28% | 61 |
|
|
2025
Q4 | $1.67M | Hold |
9,894
| – | – | 0.26% | 58 |
|
|
2025
Q3 | $1.43M | Sell |
9,894
-162
| -2% | -$22.1K | 0.22% | 64 |
|
|
2025
Q2 | $1.27M | Sell |
10,056
-104
| -1% | -$12.8K | 0.22% | 68 |
|
|
2025
Q1 | $1.3M | Sell |
10,160
-159
| -2% | -$21.6K | 0.25% | 65 |
|
|
2024
Q4 | $1.36M | Sell |
10,319
-160
| -2% | -$22.5K | 0.25% | 64 |
|
|
2024
Q3 | $1.53M | Sell |
10,479
-37
| -0.4% | -$5.35K | 0.29% | 59 |
|
|
2024
Q2 | $1.44M | Buy |
10,516
+74
| +0.7% | +$9.9K | 0.29% | 60 |
|
|
2024
Q1 | $1.43M | Sell |
10,442
-301
| -3% | -$41.1K | 0.32% | 56 |
|
|
2023
Q4 | $1.46M | Sell |
10,743
-544
| -5% | -$66.4K | 0.37% | 54 |
|
|
2023
Q3 | $1.38M | Sell |
11,287
-554
| -5% | -$70.5K | 0.4% | 57 |
|
|
2023
Q2 | $1.5M | Buy |
11,841
+260
| +2% | +$33.8K | 0.43% | 53 |
|
|
2023
Q1 | $1.51M | Buy |
11,581
+288
| +3% | +$37.7K | 0.49% | 47 |
|
|
2022
Q4 | $1.48M | Sell |
11,293
-275
| -2% | -$35.5K | 0.54% | 48 |
|
|
2022
Q3 | $1.35M | Sell |
11,568
-492
| -4% | -$61.1K | 0.51% | 51 |
|
|
2022
Q2 | $1.42M | Buy |
12,060
+589
| +5% | +$69.9K | 0.5% | 52 |
|
|
2022
Q1 | $1.49M | Sell |
11,471
-4,566
| -28% | -$595K | 0.43% | 56 |
|
|
2021
Q4 | $2.45M | Buy |
16,037
+3,721
| +30% | +$576K | 0.68% | 38 |
|
|
2021
Q3 | $1.99M | Buy |
12,316
+1,504
| +14% | +$253K | 0.61% | 42 |
|
|
2021
Q2 | $1.77M | Buy |
10,812
+112
| +1% | +$17.3K | 0.55% | 46 |
|
|
2021
Q1 | $1.61M | Buy |
10,700
+720
| +7% | +$114K | 0.55% | 50 |
|
|
2020
Q4 | $1.51M | Buy |
9,980
+1,030
| +12% | +$147K | 0.54% | 50 |
|
|
2020
Q3 | $1.21M | Sell |
8,950
-580
| -6% | -$78.7K | 0.49% | 52 |
|
|
2020
Q2 | $1.3M | Buy |
9,530
+3,222
| +51% | +$411K | 0.58% | 47 |
|
|
2020
Q1 | $679K | Buy |
6,308
+154
| +3% | +$17.7K | 0.37% | 70 |
|
|
2019
Q4 | $737K | Buy |
6,154
+806
| +15% | +$89.9K | 0.35% | 78 |
|
|
2019
Q3 | $532K | Sell |
5,348
-400
| -7% | -$41.9K | 0.28% | 85 |
|
|
2019
Q2 | $627K | Buy |
5,748
+351
| +7% | +$37.3K | 0.32% | 80 |
|
|
2019
Q1 | $603K | Buy |
5,397
+1,967
| +57% | +$216K | 0.32% | 81 |
|
|
2018
Q4 | $330K | Sell |
3,430
-1,566
| -31% | -$166K | 0.2% | 104 |
|
|
2018
Q3 | $609K | Buy |
+4,996
| New | +$588K | 0.3% | 77 |
|
Other funds holding IBB
Blue Fin Capital's IBB Position: Q3 2026 in Review
Blue Fin Capital increased its iShares Biotechnology ETF (IBB) stake by 0.32% in Q3 2026, buying an estimated $6.42K and bringing the position to 10,053 shares worth $2.12M. The position accounts for 0.29% of the portfolio, ranked #58.
Blue Fin Capital first reported a position in IBB in Q3 2018 and has held it in 33 quarters since. The position peaked at $2.45M in Q4 2021. 610 funds tracked by Wall St. Rank hold IBB as of Q3 2026.
- Blue Fin Capital held 10,053 shares of iShares Biotechnology ETF worth $2.12M as of Q3 2026.
- Blue Fin Capital bought 32 iShares Biotechnology ETF shares in Q3 2026, an estimated $6.42K.
- iShares Biotechnology ETF made up 0.29% of Blue Fin Capital's portfolio in Q3 2026, its #58 holding.
- Blue Fin Capital first reported a position in iShares Biotechnology ETF in Q3 2018 and has held it in 33 quarters since.
- Blue Fin Capital's iShares Biotechnology ETF position peaked at $2.45M in Q4 2021.
- 610 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q3 2026.
Based on Blue Fin Capital's 13F filing for Q3 2026, filed 28 Oct 2026.